Cardiovascular disease and HIV infection

Current HIV/AIDS Reports

Volumn 10, Issue 3, 2013, Pages 199-206

  Triant, Virginia A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cardiovascular; Coronary; HIV; Myocardial infarction; Risk factors

Indexed keywords

ABACAVIR; ATAZANAVIR; RALTEGRAVIR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTIVIRAL THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS (TOPIC); NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; HIV INFECTIONS; HUMANS; RISK FACTORS;

EID: 84881474087     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-013-0168-6     Document Type: Article

References (100)

1. Currier JS et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506-12. (Pubitemid 36886080)
2. Durand M et al. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database. J Acquir Immune Defic Syndr. 2011;57:245-53.
3. Klein D et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30:471-7.
4. Lang S et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010;24:1228-30.
5. Obel N et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis. 2007;44:1625-31. (Pubitemid 46871511)
6. Triant VA et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506-12. (Pubitemid 47037350)
7. • Freiberg MS et al. HIV infection and the risk of acute myocardial infarction. JAMA. 2013;173:614-22. In this study of a large VA HIV cohort, HIV infection increased risk of myocardial infarction 1.5-fold, adjusting for sociodemographic and cardiovascular confounders. This study corroborates previous data indicating an increased relative risk of myocardial infarction for HIV-infected patients.
8. Islam FM et al. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13:453-68.
9. Althoff K, Gange S. A critical epidemiological review of cardiovascular disease risk in HIV-infected adults: the importance of the HIV-uninfected comparison group, confounding, and competing risks. HIV Med. 2013;14:191-2.
10. Hsue PY et al. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation. 2004;109:316-9. (Pubitemid 38133896)
11. Knudsen A et al. Angiographic features and cardiovascular risk factors in human immunodeficiency virus-infected patients with first-time acute coronary syndrome. Am J Cardiol. 2013;111:63-7.
12. Perello R et al. Clinical presentation of acute coronary syndrome in HIV infected adults: a retrospective analysis of a prospectively collected cohort. Eur J Int Med. 2011;22:485-8.
13. Pearce D et al. Comparison of in-hospital mortality from acute myocardial infarction in HIV sero-positive vs sero-negative individuals. Am J Cardiol. 2012;110:1078-84.
14. Lorgis L et al. Outcomes after acute myocardial infarction in HIV-infected patients: analysis of data from a French nationwide hospital medical information database. Circulation. 2013;127:1767-74.
15. D'Ascenzo F et al. Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy. Eur Heart J. 2012;33:875-80.
16. Rasmussen LD et al. Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS. 2011;25:1637-46.
17. Chow FC et al. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr. 2012;60:351-8.
18. Ovbiagele B, Nath A. Increasing incidence of ischemic stroke in patients with HIV infection. Neurology. 2011;76:444-50.
19. • Tseng ZH et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol. 2012;59:1891-6. HIV-infected patients at a public San Francisco clinic had a striking 4.5-fold increased risk of sudden cardiac death, when compared with the anticipated city-wide rate. As the first study to show such an increase, it highlights the significant impact of CVD-related mortality in HIV groups and underscores the need for prevention strategies.
20. Ye Y et al. HIV infection: an independent risk factor of peripheral arterial disease. J Acquir Immune Defic Syndr. 2010;53:276-8.
21. Butt A et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011;171:737-43.
22. Hsu JC, et al. Atrial fibrillation and atrial flutter in HIV-infected persons: incidence, risk factors, and association with markers of HIV disease severity. J Am Coll Cardiol. 2013.
23. Meier A et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med. 2009;15:955-9.
24. Bedimo R et al. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med. 2010;11:462-8.
25. Freiberg MS et al. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes. 2011;4:425-32.
26. Weber R et al. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antivir Ther. 2010;15:1077-86.
27. Sacre K et al. A role for cytomegalovirus-specific CD4 + CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. AIDS. 2012;26:805-14.
28. Parrinello CM et al. Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. J Infect Dis. 2012;205:1788-96.
29. Hechter RC et al. Herpes simplex virus type 2 (HSV-2) as a coronary atherosclerosis risk factor in HIV-infected men: multicenter AIDS cohort study. Atherosclerosis. 2012;223:433-6.
30. Campbell LJ et al. Renal impairment is associated with coronary heart disease in HIV-positive men. HIV Clinical Trials. 2012;13:343-9.
31. Lai H et al. Vitamin D deficiency is associated with silent coronary artery disease in cardiovascularly asymptomatic African Americans with HIV infection. Clin Infect Dis. 2012;54:1747-55.
32. Lang J, et al. Serum albumin and short-term risk for mortality and cardiovascular disease among HIV-infected veterans. AIDS. 2013.
33. Lichtenstein KA et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis. 2010;51:435-47.
34. Triant VA et al. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr. 2010;55:615-9.
35. Lang S et al. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clin Infect Dis. 2012;55:600-7.
36. Ho JE et al. The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease. AIDS. 2012;26:1115-20.
37. Duarte H et al. Non-calcified coronary plaque volume inversely related to CD4(+) T-cell count in HIV infection. Antivir Ther. 2012;17:763-7.
38. van Lelyveld SF et al. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS. 2012;26:465-74.
39. Helleberg M, et al. CD4 decline is associated with increased risk of cardiovascular disease, cancer and death in virally suppressed HIV patients. Clin Infect Dis. 2013.
40. Zhang S et al. Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr. 2012;60:265-72.
41. Bucher HC et al. Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2012;60:135-42.
42. Lucero C, et al. Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm3. AIDS Research and Human Retroviruses. 2013.
43. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62. (Pubitemid 40075680)
44. Rotger M, et al. Contribution of genetic background, traditional risk factors and HIV-related factors to coronary artery disease events in HIV-positive persons. Clin Infect Dis. 2013.
45. Friis-Moller N et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-35. (Pubitemid 46658704)
46. Worm SW et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318-30.
47. Lang S et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in Human Immunodeficiency Virus-infected patients: a case-control study nested within the French hospital database on HIV ANRS cohort CO4. Arch Intern Med. 2010;170:1228-38.
48. Monforte A et al. Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. AIDS. 2013;27:407-15.
49. Bavinger C et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One. 2013;8:e59551.
50. Cruciani M et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS. 2011;25:1993-2004.
51. Ding X et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 2012;61:441-7.
52. El-Sadr WM et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-96. (Pubitemid 44837777)
53. Zanni MV, Grinspoon SK. HIV-specific immune dysregulation and atherosclerosis. Curr HIV/AIDS Rpts. 2012;9:200-5.
54. Lo J, Plutzky J. The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patients. J Infect Dis. 2012;205 Suppl 3:S368-74.
55. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141-55.
56. Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rpts. 2012;9:139-47.
57. Armah KA et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis. 2012;55:126-36.
58. Hsue PY, et al. Carotid intima-media thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation. JAMA. 2012;1.
59. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009;51:268-73.
60. Ford ES et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS. 2010;24:1509-17.
61. Tien PC et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr. 2010;55:316-22.
62. Duprez DA et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7:e44454.
63. Kaplan RC et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infec Dis. 2011;203:452-63.
64. Longenecker C, et al. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med. 2013.
65. Stein JH, et al. Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS. 2012.
66. • Subramanian S et al. Arterial inflammation in patients with HIV. JAMA. 2012;308:379-86. Arterial inflammation as assessed by target-to-background ratio in FDG-PET was significantly increased in HIV-infected patients compared with matched control patients with similar cardiovascular risk. Monocyte activation marker sCD163 was significantly associated with arterial inflammation, reinforcing the hypothesis that immune activation plays a significant role in HIV-associated CVD.
67. • Zanni MV, et al. Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. AIDS. 2013. In this cross-disciplinary study utilizing advanced cardiovascular imaging techniques, HIV-infected patients had a higher prevalence of vulnerability features of coronary plaque.
68. Mendez-Lagares G et al. Long-term suppressive combined antiretroviral treatment does not normalize the serum level of Soluble CD14. J Infec Dis. 2013;207:1221-5.
69. French MA et al. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infec Dis. 2009;200:1212-5.
70. Hsue PY et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23:1059-67.
71. Pereyra F et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS. 2012;26:2409-12.
72. Funderburg NT et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood. 2012;120:4599-608.
73. Dube MP et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-27. (Pubitemid 37100800)
74. Aberg JA et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:651-81.
75. D'Agostino Sr RB. Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population. J Infect Dis. 2012;205 Suppl 3:S362-7.
76. Friis-Moller N et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehab: Off J Eur Soc Cardiol, Work Groups Epidemiol Prev Cardiac Rehab Exerc Physiol. 2010;17:491-501.
77. Lichtenstein KA et al. Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients. Preventing Chronic Disease. 2013;10:E10.
78. Reinsch N et al. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiol. 2012;19:267-74.
79. Burkholder GA et al. Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. Clin Infect Dis. 2012;55:1550-7.
80. Tornero CA, Ventura, Mafe M. Aspirin is indicated for primary prevention of cardiovascular events in HIV-infected patients. J Acquir Immune Defic Syndr. 2010;54:560.
81. • Helleberg M et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56:727-34. HIV-infected patients lost more life years to smoking than to HIV, in this striking recent study. These results underscore the critical importance of smoking cessation in HIV groups and provide a strong message, which providers can relay to patients.
82. Lifson AR et al. Smoking-related health risks among persons with HIV in the strategies for management of antiretroviral therapy clinical trial. Am J Public Health. 2010;100:1896-903.
83. Petoumenos K et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study (*). HIV Med. 2011;12:412-21.
84. Lifson AR, Lando HA. Smoking and HIV: prevalence, health risks, and cessation strategies. Curr HIV/AIDS Rpts. 2012;9:223-30.
85. Niaura R et al. Interventions to address chronic disease and HIV: strategies to promote smoking cessation among HIV-infected individuals. Curr HIV/AIDS Rpts. 2012;9:375-84.
86. Vidrine DJ et al. Efficacy of cell phone-delivered smoking cessation counseling for persons living with HIV/AIDS: 3-month outcomes. Nicotine Tob Res. 2012;14:106-10.
87. Huber M et al. Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians. HIV Med. 2012;13:387-97.
88. Ganesan A et al. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011;203:756-64.
89. Calza L et al. Statin therapy decreases serum levels of high-sensitivity c-reactive protein and tumor necrosis factor-alpha in HIV-infected patients treated with ritonavir-boosted protease inhibitors. HIV Clin Trials. 2012;13:153-61.
90. Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One. 2011;6:e21843.
91. Rasmussen LD et al. Statin therapy and mortality in HIV-Infected individuals: a Danish nationwide population-based cohort study. PLoS One. 2013;8:e52828.
92. Calza L et al. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk. AIDS Res Hum Retroviruses. 2013;29:547-56.
93. O'Brien M, et al. Aspirin attenuates platelet activation and immune activation in HIV-infected subjects on antiretroviral therapy: a pilot study. J Acquir Immune Defic Syndr. 2013.
94. • Paton NI et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA. 2012;308:353-61. Contrary to the hypothesized result, hydroxychloroquine did not reduce T cell activation among HIV-infected patients in this clinical trial. Moreover, patients randomized to the intervention arm had increased T cell decline and viral replication. These unexpected results emphasize the challenges of designing interventions to target immune activation in HIV-infected patients.
95. Hatano H et al. A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection. J Acquir Immune Defic Syndr. 2012;61:317-25.
96. Green LA et al. Pentoxifylline reduces tumor necrosis factor-alpha and HIV-induced vascular endothelial activation. AIDS Res Hum Retroviruses. 2012;28:1207-15.
97. Baker JV et al. Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial. PLoS One. 2012;7:e46894.
98. Longenecker CT et al. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther. 2012;17:613-21.
99. Stein JH, Hsue PY. Inflammation, immune activation, and CVD risk in individuals with HIV infection. JAMA. 2012;308:405-6.
100. Negoescu DM et al. Balancing immunological benefits and cardiovascular risks of antiretroviral therapy: when is immediate treatment optimal? Clin Infect Dis. 2012;55:1392-9.